Showing results (81-90 of 160) with videos related to

Sort By:
Pageof 16
European Journal of Nuclear Medicine and Molecular Imaging|May 6, 2023
Detection efficacy of [89Zr]Zr-PSMA-617 PET/CT in [68Ga]Ga-PSMA-11 PET/CT-negative biochemical recurrence of prostate cancerFlorian Rosar, Fadi Khreish, Robert J Marlowe, et al.
The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|July 3, 2025
Tumor sink effect in PSMA-targeted theranostics: intra-patient evaluation of a cohort receiving 225Ac/177Lu-PSMA tandem radioligand therapyCaroline Burgard, Marie D Muenzenberg, Arne Blickle, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 7, 2013
Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotateAmir Sabet, Khaled Ezziddin, Ulrich-Frank Pape, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 15, 2024
Efficacy and safety of rechallenge [177Lu]Lu-PSMA-617 RLT after initial partial remission in patients with mCRPC: evaluation of a prospective registry (REALITY study)Florian Rosar, Joelle Schuler, Caroline Burgard, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 24, 2019
225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experienceFadi Khreish, Niklas Ebert, Martin Ries, et al.
Endocrine-Related Cancer|June 30, 2016
Myeloid neoplasms after chemotherapy and PRRT: myth and realityLisa Bodei, Irvin M Modlin, Markus Luster, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 30, 2014
Early post-treatment FDG PET predicts survival after 90Y microsphere radioembolization in liver-dominant metastatic colorectal cancerAmir Sabet, Carsten Meyer, Anas Aouf, et al.
Cancers|August 27, 2021
Value of Combined PET Imaging with [18F]FDG and [68Ga]Ga-PSMA-11 in mCRPC Patients with Worsening Disease during [177Lu]Lu-PSMA-617 RLTFadi Khreish, Kalle Ribbat, Mark Bartholomä, et al.
Nuclear Medicine and Biology|June 1, 2025
Radiochemistry of cyclen-derived chelators comprising five-membered azaheterocyclic arms with 212Pb2+, 213Bi3+, and 225Ac3Ina Hierlmeier, Parmissa Randhawa, Brooke L McNeil, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 18, 2018
EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclidesDaria Handkiewicz-Junak, Thorsten D Poeppel, Lisa Bodei, et al.
Pageof 16